A detailed history of Rafferty Asset Management, LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 289,385 shares of IMVT stock, worth $7.96 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
289,385
Previous 229,087 26.32%
Holding current value
$7.96 Million
Previous $9.65 Million 3.12%
% of portfolio
0.04%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$30.27 - $43.79 $1.83 Million - $2.64 Million
60,298 Added 26.32%
289,385 $9.35 Million
Q4 2023

Feb 13, 2024

SELL
$31.31 - $44.19 $2.12 Million - $2.99 Million
-67,745 Reduced 22.82%
229,087 $9.65 Million
Q3 2023

Nov 13, 2023

BUY
$18.55 - $39.96 $838,664 - $1.81 Million
45,211 Added 17.97%
296,832 $11.4 Million
Q2 2023

Aug 11, 2023

SELL
$14.2 - $23.75 $1.08 Million - $1.81 Million
-76,295 Reduced 23.27%
251,621 $4.77 Million
Q1 2023

May 11, 2023

BUY
$15.27 - $19.72 $1.49 Million - $1.92 Million
97,343 Added 42.22%
327,916 $5.09 Million
Q4 2022

Feb 13, 2023

BUY
$6.59 - $17.75 $1.52 Million - $4.09 Million
230,573 New
230,573 $4.09 Million
Q1 2022

May 13, 2022

SELL
$5.06 - $8.77 $961,025 - $1.67 Million
-189,926 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$7.33 - $9.32 $4,471 - $5,685
610 Added 0.32%
189,926 $1.62 Million
Q3 2021

Nov 10, 2021

SELL
$7.01 - $11.37 $125,289 - $203,216
-17,873 Reduced 8.63%
189,316 $1.65 Million
Q2 2021

Aug 10, 2021

BUY
$9.4 - $16.85 $104,255 - $186,883
11,091 Added 5.66%
207,189 $2.19 Million
Q1 2021

May 10, 2021

BUY
$13.08 - $49.6 $2.34 Million - $8.88 Million
179,130 Added 1055.69%
196,098 $3.15 Million
Q4 2020

Feb 10, 2021

SELL
$36.36 - $52.71 $166,056 - $240,726
-4,567 Reduced 21.21%
16,968 $784,000
Q3 2020

Nov 13, 2020

BUY
$22.61 - $38.9 $486,906 - $837,711
21,535 New
21,535 $758,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.